Lemos Cláudia, Ferreira Sofia, Gouveia Cláudio, Mendonça Érica, Mota Ana Marta, Rodrigues Mariana, Alves José, Chaves Susana, Andrade Graça, Nóbrega José J
Intensive Care Department, Hospital Central do Funchal, Funchal, PRT.
Internal Medicine, Centro Hospitalar Lisboa Ocidental, Lisbon, PRT.
Cureus. 2021 Dec 21;13(12):e20579. doi: 10.7759/cureus.20579. eCollection 2021 Dec.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) emerged in China in December 2019. Healthcare workers (HCWs) are one of the high-risk groups of infection and knowledge of the seroprevalence of SARS-CoV-2 antibodies among this class is very important, not only to understand the spread of COVID-19 among health institutions but also to assess the success of public health interventions. The objective of this prospective study was to determine the seroprevalence of COVID-19 immunoglobulin G (IgG) antibodies after vaccine administration and assess the symptomatology associated with the number of IgG antibodies. A total of 75 HCWs from an intensive care unit were studied three and six months after the second administration of the COVID-19 vaccine. They were divided into three groups: IgG antibodies between 4,160 and 6,350 (group one), greater than 6,350 (group two), and less than 4,160 (group three). After the first administration of the vaccine, 80% had symptoms in both groups one and two, whereas only 13.8% had symptoms in group three. After the second dose of the vaccine, all elements of group one and 80% of group two developed symptoms, but only 40% of group three manifested symptoms. With the exception of one, all professionals showed a decrease in the number of IgG antibodies from three to six months. Our findings show that professionals with a higher number of IgG antibodies had more symptoms and that these rapidly declined over the three-to-six-month period.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和2019冠状病毒病（COVID-19）于2019年12月在中国出现。医护人员是感染的高危群体之一，了解该群体中SARS-CoV-2抗体的血清流行率非常重要，这不仅有助于了解COVID-19在医疗机构中的传播情况，还能评估公共卫生干预措施的成效。这项前瞻性研究的目的是确定接种疫苗后COVID-19免疫球蛋白G（IgG）抗体的血清流行率，并评估与IgG抗体数量相关的症状表现。对一家重症监护病房的75名医护人员在第二次接种COVID-19疫苗后的三个月和六个月进行了研究。他们被分为三组：IgG抗体在4160至6350之间（第一组）、大于6350（第二组）和小于4160（第三组）。在首次接种疫苗后，第一组和第二组中80%的人出现了症状，而第三组中只有13.8%的人出现了症状。在接种第二剂疫苗后，第一组的所有人和第二组的80%出现了症状，但第三组只有40%出现了症状。除一人外，所有专业人员的IgG抗体数量在三个月至六个月期间都有所下降。我们的研究结果表明，IgG抗体数量较多的专业人员症状更多，且这些症状在三至六个月期间迅速减少。
